San Francisco Sentry Investment Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

San Francisco Sentry Investment Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$22K	Sell	262 -4	-2%	-$317	0.01%	461
2021 Q1	$20K	Hold	266	–	–	0.01%	492
2020 Q4	$23K	Sell	266 -22	-8%	-$1.74K	0.01%	447
2020 Q3	$22K	Sell	288 -7	-2%	-$708	0.01%	421
2020 Q2	$36K	Sell	295 -2	-0.7%	-$199	0.02%	364
2020 Q1	$25K	Sell	297 -22	-7%	-$1.9K	0.02%	358
2019 Q4	$27K	Hold	319	–	–	0.01%	449
2019 Q3	$21K	Sell	319 -7	-2%	-$539	0.01%	476
2019 Q2	$28K	Sell	326 -84	-20%	-$7.19K	0.01%	439
2019 Q1	$36K	Buy	410 +177	+76%	+$16.4K	0.02%	428
2018 Q4	$20K	Sell	233 -20	-8%	-$1.9K	0.01%	476
2018 Q3	$24K	Buy	253 +231	+1,050%	+$23.1K	0.01%	480
2018 Q2	$2K	Hold	22	–	–	﹤0.01%	689
2018 Q1	$2K	Buy	+22	New	+$1.89K	﹤0.01%	835
2017 Q3	–	Sell	-50	Closed	-$5K	–	915
2017 Q2	$5K	Buy	+50	New	+$4.55K	﹤0.01%	595

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

San Francisco Sentry Investment Group's BMRN Position: Q2 2021 in Review

San Francisco Sentry Investment Group reduced its BioMarin Pharmaceuticals (BMRN) stake by 1.5% in Q2 2021, selling an estimated $317 and leaving 262 shares worth $22K. The position accounts for 0.01% of the portfolio, ranked #461.

San Francisco Sentry Investment Group first reported a position in BMRN in Q2 2017 and has held it in 15 quarters since. The position peaked at $36K in Q2 2020. 530 funds tracked by Wall St. Rank hold BMRN as of Q2 2021.

San Francisco Sentry Investment Group held 262 shares of BioMarin Pharmaceuticals worth $22K as of Q2 2021.
San Francisco Sentry Investment Group sold 4 BioMarin Pharmaceuticals shares in Q2 2021, an estimated $317.
BioMarin Pharmaceuticals made up 0.01% of San Francisco Sentry Investment Group's portfolio in Q2 2021, its #461 holding.
San Francisco Sentry Investment Group first reported a position in BioMarin Pharmaceuticals in Q2 2017 and has held it in 15 quarters since.
San Francisco Sentry Investment Group's BioMarin Pharmaceuticals position peaked at $36K in Q2 2020.
530 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2021.

Based on San Francisco Sentry Investment Group's 13F filing for Q2 2021, filed 2 Aug 2021.